C2N Diagnostics Receives FDA Clearance for PrecivityAD2 Alzheimer’s Blood Test for Adults as Young as 40
C2N Diagnostics has received FDA clearance for its PrecivityAD2 blood test, the first Alzheimer’s diagnostic aid cleared for use in symptomatic adults aged 40 and older, delivering high diagnostic performance to help clinicians rule in or rule out clinical Alzheimer’s disease.
更多内容